POST-MASTECTOMY RADIATION THERAPY AFTER BREAST RECONSTRUCTION: FROM HISTORIC DOGMAS TO PRACTICAL EXPERT AGREEMENTS BASED ON A LARGE LITERATURE REVIEW OF SURGICAL AND RADIATION THERAPY CONSIDERATIONS.

Breast cancer DIEP PMRT breast reconstruction cosmesis flap mastectomy prosthesis radiation therapy toxicity

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
12 Jun 2024
Historique:
received: 10 12 2023
revised: 08 06 2024
accepted: 10 06 2024
medline: 15 6 2024
pubmed: 15 6 2024
entrez: 14 6 2024
Statut: aheadofprint

Résumé

Breast reconstruction (BR) after mastectomy is important to consider for a woman's body image enhancement and psychological well-being. Although post-mastectomy radiation (PMRT) significantly improves the outcome of patients with high-risk breast cancer (BC), PMRT after BR may affect cosmetic outcomes and may compromise the original goal of improving quality of life (QoL). With the lack of practical guidelines, it seems essential to work on a consensus and provide some "expert agreements" to offer patients the best option for PMRT after BR. We report a global "expert agreement" that results from a critical review of the literature on BR and PMRT during the 6th international multidisciplinary breast conference in March 2023.

Identifiants

DOI: 10.1016/j.critrevonc.2024.104421 PMID: 38876160
pubmed: 38876160
pii: S1040-8428(24)00164-1
doi: 10.1016/j.critrevonc.2024.104421
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104421

Informations de copyright

Copyright © 2024. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of Competing Interest None

Auteurs

Yazid Belkacemi (Y)

AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital. University of Paris Est Creteil (UPEC). France; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, i-Biot, UPEC, Créteil, France. Electronic address: yazid.belkacemi@aphp.fr.

Meena S Moran (MS)

Smilow Cancer Center, Yale University School of Medicine. Department of Therapeutic Radiology, New Haven, CT USA.

Burcu Celet Ozden (BC)

Istanbul Breast Clinic, Istanbul, Turkey.

Yazan Masannat (Y)

Broomfield Hospital, Mid and South Essex NHS Trust, England, UK.

Fady Geara (F)

Department of Radiation Oncology, Oncology Institute, Cleveland Clinic Abu Dhabi. UAE.

Mohamed Albashir (M)

Levantine Medical Center, Ain Alkhaleej Hospital and Burjeel Royal Hospital. Alain, UAE.

Nhu Hanh To (NH)

AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital. University of Paris Est Creteil (UPEC). France; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, i-Biot, UPEC, Créteil, France.

Kamel Debbi (K)

AP-HP, Department of Radiation Oncology and Henri Mondor Breast Center, Henri Mondor University Hospital. University of Paris Est Creteil (UPEC). France; Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, i-Biot, UPEC, Créteil, France.

Mahmoud El Tamer (M)

Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, New York, USA.

Classifications MeSH